Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice
Given their relative simplicity of manufacture and ability to be injected repeatedly, vaccines in a protein format are attractive for breast and other cancers. However, soluble human epidermal growth factor receptor (HER2)/neu protein as a vaccine has not been immunogenic. When protein is directly t...
Saved in:
| Published in: | Breast cancer research : BCR Vol. 14; no. 2; p. R39 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
England
BioMed Central Ltd
07-03-2012
BioMed Central |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Given their relative simplicity of manufacture and ability to be injected repeatedly, vaccines in a protein format are attractive for breast and other cancers. However, soluble human epidermal growth factor receptor (HER2)/neu protein as a vaccine has not been immunogenic. When protein is directly targeted to antigen uptake receptors, such as DEC205 (DEC), efficient processing and presentation of antigen take place. The aim of this study was to determine the immunogenicity of a HER2 protein vaccine that directly targets to DEC+ dendritic cells (DCs) in a mouse breast cancer model.
We genetically engineered the HER2 extracellular domain into a monoclonal antibody specific for DEC (DEC-HER2). Mice of various genetic backgrounds were immunized with DEC-HER2 in combination with DC maturation stimuli (poly IC ± CD40 Ab). Vaccine-induced T cell immunity was determined by analyzing the ability of CD4+/CD8+ T cell to produce interferon (IFN)-gamma and proliferate upon antigen rechallenge. Sera were assessed for the presence of antigen specific antibody (Ab). For vaccine efficacy, FVB/N mice were immunized with DEC-HER2 in combination with poly IC and protection against neu-expressing mammary tumors was assessed. Protection mechanisms and tumor-specific T cell responses were also evaluated.
We demonstrate that DEC-HER2 fusion mAb, but not Ctrl Ig-HER2, elicits strong, broad and multifunctional CD4+ T cell immunity, CD8+ T cell responses, and humoral immunity specific for HER2 antigen. Cross-reactivity to rat neu protein was also observed. Importantly, mice xeno-primed with DEC-HER2 were protected from a neu-expressing mammary tumor challenge. Both CD4+ and CD8+ T cells mediated the tumor protection. Robust anti-tumor T cell immunity was detected in tumor protected mice.
Immunization of mice with HER2 protein vaccine targeting DEC+ DCs in vivo induced high levels of T- and B-cell immunity. Non-targeted HER2 protein was poorly immunogenic for CD4+ and CD8+ T cells. This vaccination approach provided long-term survival benefit for mice challenged with neu-expressing tumor following as little as 2.7 μg of HER2 protein incorporated in the vaccine. Vaccine-induced CD4+ and CD8+ T cells were both essential for tumor protection. This immunization strategy demonstrates great potential towards the development of vaccines for breast cancer patients. |
|---|---|
| AbstractList | INTRODUCTIONGiven their relative simplicity of manufacture and ability to be injected repeatedly, vaccines in a protein format are attractive for breast and other cancers. However, soluble human epidermal growth factor receptor (HER2)/neu protein as a vaccine has not been immunogenic. When protein is directly targeted to antigen uptake receptors, such as DEC205 (DEC), efficient processing and presentation of antigen take place. The aim of this study was to determine the immunogenicity of a HER2 protein vaccine that directly targets to DEC+ dendritic cells (DCs) in a mouse breast cancer model. METHODSWe genetically engineered the HER2 extracellular domain into a monoclonal antibody specific for DEC (DEC-HER2). Mice of various genetic backgrounds were immunized with DEC-HER2 in combination with DC maturation stimuli (poly IC ± CD40 Ab). Vaccine-induced T cell immunity was determined by analyzing the ability of CD4+/CD8+ T cell to produce interferon (IFN)-gamma and proliferate upon antigen rechallenge. Sera were assessed for the presence of antigen specific antibody (Ab). For vaccine efficacy, FVB/N mice were immunized with DEC-HER2 in combination with poly IC and protection against neu-expressing mammary tumors was assessed. Protection mechanisms and tumor-specific T cell responses were also evaluated. RESULTSWe demonstrate that DEC-HER2 fusion mAb, but not Ctrl Ig-HER2, elicits strong, broad and multifunctional CD4+ T cell immunity, CD8+ T cell responses, and humoral immunity specific for HER2 antigen. Cross-reactivity to rat neu protein was also observed. Importantly, mice xeno-primed with DEC-HER2 were protected from a neu-expressing mammary tumor challenge. Both CD4+ and CD8+ T cells mediated the tumor protection. Robust anti-tumor T cell immunity was detected in tumor protected mice. CONCLUSIONSImmunization of mice with HER2 protein vaccine targeting DEC+ DCs in vivo induced high levels of T- and B-cell immunity. Non-targeted HER2 protein was poorly immunogenic for CD4+ and CD8+ T cells. This vaccination approach provided long-term survival benefit for mice challenged with neu-expressing tumor following as little as 2.7 μg of HER2 protein incorporated in the vaccine. Vaccine-induced CD4+ and CD8+ T cells were both essential for tumor protection. This immunization strategy demonstrates great potential towards the development of vaccines for breast cancer patients. Given their relative simplicity of manufacture and ability to be injected repeatedly, vaccines in a protein format are attractive for breast and other cancers. However, soluble human epidermal growth factor receptor (HER2)/neu protein as a vaccine has not been immunogenic. When protein is directly targeted to antigen uptake receptors, such as DEC205 (DEC), efficient processing and presentation of antigen take place. The aim of this study was to determine the immunogenicity of a HER2 protein vaccine that directly targets to DEC+ dendritic cells (DCs) in a mouse breast cancer model. We genetically engineered the HER2 extracellular domain into a monoclonal antibody specific for DEC (DEC-HER2). Mice of various genetic backgrounds were immunized with DEC-HER2 in combination with DC maturation stimuli (poly IC ± CD40 Ab). Vaccine-induced T cell immunity was determined by analyzing the ability of CD4+/CD8+ T cell to produce interferon (IFN)-gamma and proliferate upon antigen rechallenge. Sera were assessed for the presence of antigen specific antibody (Ab). For vaccine efficacy, FVB/N mice were immunized with DEC-HER2 in combination with poly IC and protection against neu-expressing mammary tumors was assessed. Protection mechanisms and tumor-specific T cell responses were also evaluated. We demonstrate that DEC-HER2 fusion mAb, but not Ctrl Ig-HER2, elicits strong, broad and multifunctional CD4+ T cell immunity, CD8+ T cell responses, and humoral immunity specific for HER2 antigen. Cross-reactivity to rat neu protein was also observed. Importantly, mice xeno-primed with DEC-HER2 were protected from a neu-expressing mammary tumor challenge. Both CD4+ and CD8+ T cells mediated the tumor protection. Robust anti-tumor T cell immunity was detected in tumor protected mice. Immunization of mice with HER2 protein vaccine targeting DEC+ DCs in vivo induced high levels of T- and B-cell immunity. Non-targeted HER2 protein was poorly immunogenic for CD4+ and CD8+ T cells. This vaccination approach provided long-term survival benefit for mice challenged with neu-expressing tumor following as little as 2.7 μg of HER2 protein incorporated in the vaccine. Vaccine-induced CD4+ and CD8+ T cells were both essential for tumor protection. This immunization strategy demonstrates great potential towards the development of vaccines for breast cancer patients. Introduction Given their relative simplicity of manufacture and ability to be injected repeatedly, vaccines in a protein format are attractive for breast and other cancers. However, soluble human epidermal growth factor receptor (HER2)/neu protein as a vaccine has not been immunogenic. When protein is directly targeted to antigen uptake receptors, such as DEC205 (DEC), efficient processing and presentation of antigen take place. The aim of this study was to determine the immunogenicity of a HER2 protein vaccine that directly targets to DEC.sup.+ .sup.dendritic cells (DCs) in a mouse breast cancer model. Methods We genetically engineered the HER2 extracellular domain into a monoclonal antibody specific for DEC (DEC-HER2). Mice of various genetic backgrounds were immunized with DEC-HER2 in combination with DC maturation stimuli (poly IC [+ -] CD40 Ab). Vaccine-induced T cell immunity was determined by analyzing the ability of CD4.sup.+.sup./CD8.sup.+ .sup.T cell to produce interferon (IFN)-gamma and proliferate upon antigen rechallenge. Sera were assessed for the presence of antigen specific antibody (Ab). For vaccine efficacy, FVB/N mice were immunized with DEC-HER2 in combination with poly IC and protection against neu-expressing mammary tumors was assessed. Protection mechanisms and tumor-specific T cell responses were also evaluated. Results We demonstrate that DEC-HER2 fusion mAb, but not Ctrl Ig-HER2, elicits strong, broad and multifunctional CD4.sup.+ .sup.T cell immunity, CD8.sup.+ .sup.T cell responses, and humoral immunity specific for HER2 antigen. Cross-reactivity to rat neu protein was also observed. Importantly, mice xeno-primed with DEC-HER2 were protected from a neu-expressing mammary tumor challenge. Both CD4.sup.+ .sup.and CD8.sup.+ .sup.T cells mediated the tumor protection. Robust anti-tumor T cell immunity was detected in tumor protected mice. Conclusions Immunization of mice with HER2 protein vaccine targeting DEC.sup.+ .sup.DCs in vivo induced high levels of T- and B-cell immunity. Non-targeted HER2 protein was poorly immunogenic for CD4.sup.+ .sup.and CD8.sup.+ .sup.T cells. This vaccination approach provided long-term survival benefit for mice challenged with neu-expressing tumor following as little as 2.7 [mu]g of HER2 protein incorporated in the vaccine. Vaccine-induced CD4.sup.+ .sup.and CD8.sup.+ .sup.T cells were both essential for tumor protection. This immunization strategy demonstrates great potential towards the development of vaccines for breast cancer patients. INTRODUCTION: Given their relative simplicity of manufacture and ability to be injected repeatedly, vaccines in a protein format are attractive for breast and other cancers. However, soluble human epidermal growth factor receptor (HER2)/neu protein as a vaccine has not been immunogenic. When protein is directly targeted to antigen uptake receptors, such as DEC205 (DEC), efficient processing and presentation of antigen take place. The aim of this study was to determine the immunogenicity of a HER2 protein vaccine that directly targets to DEC+ dendritic cells (DCs) in a mouse breast cancer model. METHODS: We genetically engineered the HER2 extracellular domain into a monoclonal antibody specific for DEC (DEC-HER2). Mice of various genetic backgrounds were immunized with DEC-HER2 in combination with DC maturation stimuli (poly IC ± CD40 Ab). Vaccine-induced T cell immunity was determined by analyzing the ability of CD4+/CD8+ T cell to produce interferon (IFN)-gamma and proliferate upon antigen rechallenge. Sera were assessed for the presence of antigen specific antibody (Ab). For vaccine efficacy, FVB/N mice were immunized with DEC-HER2 in combination with poly IC and protection against neu-expressing mammary tumors was assessed. Protection mechanisms and tumor-specific T cell responses were also evaluated. RESULTS: We demonstrate that DEC-HER2 fusion mAb, but not Ctrl Ig-HER2, elicits strong, broad and multifunctional CD4+ T cell immunity, CD8+ T cell responses, and humoral immunity specific for HER2 antigen. Cross-reactivity to rat neu protein was also observed. Importantly, mice xeno-primed with DEC-HER2 were protected from a neu-expressing mammary tumor challenge. Both CD4+ and CD8+ T cells mediated the tumor protection. Robust anti-tumor T cell immunity was detected in tumor protected mice. CONCLUSIONS: Immunization of mice with HER2 protein vaccine targeting DEC+ DCs in vivo induced high levels of T- and B-cell immunity. Non-targeted HER2 protein was poorly immunogenic for CD4+ and CD8+ T cells. This vaccination approach provided long-term survival benefit for mice challenged with neu-expressing tumor following as little as 2.7 μg of HER2 protein incorporated in the vaccine. Vaccine-induced CD4+ and CD8+ T cells were both essential for tumor protection. This immunization strategy demonstrates great potential towards the development of vaccines for breast cancer patients. Given their relative simplicity of manufacture and ability to be injected repeatedly, vaccines in a protein format are attractive for breast and other cancers. However, soluble human epidermal growth factor receptor (HER2)/neu protein as a vaccine has not been immunogenic. When protein is directly targeted to antigen uptake receptors, such as DEC205 (DEC), efficient processing and presentation of antigen take place. The aim of this study was to determine the immunogenicity of a HER2 protein vaccine that directly targets to DEC.sup.+ .sup.dendritic cells (DCs) in a mouse breast cancer model. We genetically engineered the HER2 extracellular domain into a monoclonal antibody specific for DEC (DEC-HER2). Mice of various genetic backgrounds were immunized with DEC-HER2 in combination with DC maturation stimuli (poly IC [+ -] CD40 Ab). Vaccine-induced T cell immunity was determined by analyzing the ability of CD4.sup.+.sup./CD8.sup.+ .sup.T cell to produce interferon (IFN)-gamma and proliferate upon antigen rechallenge. Sera were assessed for the presence of antigen specific antibody (Ab). For vaccine efficacy, FVB/N mice were immunized with DEC-HER2 in combination with poly IC and protection against neu-expressing mammary tumors was assessed. Protection mechanisms and tumor-specific T cell responses were also evaluated. We demonstrate that DEC-HER2 fusion mAb, but not Ctrl Ig-HER2, elicits strong, broad and multifunctional CD4.sup.+ .sup.T cell immunity, CD8.sup.+ .sup.T cell responses, and humoral immunity specific for HER2 antigen. Cross-reactivity to rat neu protein was also observed. Importantly, mice xeno-primed with DEC-HER2 were protected from a neu-expressing mammary tumor challenge. Both CD4.sup.+ .sup.and CD8.sup.+ .sup.T cells mediated the tumor protection. Robust anti-tumor T cell immunity was detected in tumor protected mice. Immunization of mice with HER2 protein vaccine targeting DEC.sup.+ .sup.DCs in vivo induced high levels of T- and B-cell immunity. Non-targeted HER2 protein was poorly immunogenic for CD4.sup.+ .sup.and CD8.sup.+ .sup.T cells. This vaccination approach provided long-term survival benefit for mice challenged with neu-expressing tumor following as little as 2.7 [mu]g of HER2 protein incorporated in the vaccine. Vaccine-induced CD4.sup.+ .sup.and CD8.sup.+ .sup.T cells were both essential for tumor protection. This immunization strategy demonstrates great potential towards the development of vaccines for breast cancer patients. Given their relative simplicity of manufacture and ability to be injected repeatedly, vaccines in a protein format are attractive for breast and other cancers. However, soluble human epidermal growth factor receptor (HER2)/neu protein as a vaccine has not been immunogenic. When protein is directly targeted to antigen uptake receptors, such as DEC205 (DEC), efficient processing and presentation of antigen take place. The aim of this study was to determine the immunogenicity of a HER2 protein vaccine that directly targets to DEC+ dendritic cells (DCs) in a mouse breast cancer model. We genetically engineered the HER2 extracellular domain into a monoclonal antibody specific for DEC (DEC-HER2). Mice of various genetic backgrounds were immunized with DEC-HER2 in combination with DC maturation stimuli (poly IC plus or minus CD40 Ab). Vaccine-induced T cell immunity was determined by analyzing the ability of CD4+/CD8+ T cell to produce interferon (IFN)-gamma and proliferate upon antigen rechallenge. Sera were assessed for the presence of antigen specific antibody (Ab). For vaccine efficacy, FVB/N mice were immunized with DEC-HER2 in combination with poly IC and protection against neu-expressing mammary tumors was assessed. Protection mechanisms and tumor-specific T cell responses were also evaluated. We demonstrate that DEC-HER2 fusion mAb, but not Ctrl Ig-HER2, elicits strong, broad and multifunctional CD4+ T cell immunity, CD8+ T cell responses, and humoral immunity specific for HER2 antigen. Cross-reactivity to rat neu protein was also observed. Importantly, mice xeno-primed with DEC-HER2 were protected from a neu-expressing mammary tumor challenge. Both CD4+ and CD8+ T cells mediated the tumor protection. Robust anti-tumor T cell immunity was detected in tumor protected mice. Immunization of mice with HER2 protein vaccine targeting DEC+ DCs in vivo induced high levels of T- and B-cell immunity. Non-targeted HER2 protein was poorly immunogenic for CD4+ and CD8+ T cells. This vaccination approach provided long-term survival benefit for mice challenged with neu-expressing tumor following as little as 2.7 mu g of HER2 protein incorporated in the vaccine. Vaccine-induced CD4+ and CD8+ T cells were both essential for tumor protection. This immunization strategy demonstrates great potential towards the development of vaccines for breast cancer patients. |
| ArticleNumber | R39 |
| Audience | Academic |
| Author | Wang, Bei Steinman, Ralph M Zaidi, Neeha Zhang, Li Kuroiwa, Janelle M Y Keler, Tibor He, Li-Zhen |
| AuthorAffiliation | 2 Celldex Therapeutics, Inc., 222 Cameron Drive, Suite 400, Phillipsburg, NJ 08865, USA 1 Laboratory of Cellular Physiology and Immunology and Chris Browne Center of Immunology and Immune Disease, The Rockefeller University, 1230 York Ave, New York, NY 10065, USA |
| AuthorAffiliation_xml | – name: 1 Laboratory of Cellular Physiology and Immunology and Chris Browne Center of Immunology and Immune Disease, The Rockefeller University, 1230 York Ave, New York, NY 10065, USA – name: 2 Celldex Therapeutics, Inc., 222 Cameron Drive, Suite 400, Phillipsburg, NJ 08865, USA |
| Author_xml | – sequence: 1 givenname: Bei surname: Wang fullname: Wang, Bei email: bwang@rockefeller.edu organization: Laboratory of Cellular Physiology and Immunology and Chris Browne Center of Immunology and Immune Disease, The Rockefeller University, 1230 York Ave, New York, NY 10065, USA. bwang@rockefeller.edu – sequence: 2 givenname: Neeha surname: Zaidi fullname: Zaidi, Neeha – sequence: 3 givenname: Li-Zhen surname: He fullname: He, Li-Zhen – sequence: 4 givenname: Li surname: Zhang fullname: Zhang, Li – sequence: 5 givenname: Janelle M Y surname: Kuroiwa fullname: Kuroiwa, Janelle M Y – sequence: 6 givenname: Tibor surname: Keler fullname: Keler, Tibor – sequence: 7 givenname: Ralph M surname: Steinman fullname: Steinman, Ralph M |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/22397502$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFktuKFDEQhhtZcQ-KbyABL_Smd3PujBfCsqyusCDICt6FdLq6N9JJxiQt-DS-qhlnXGZAkVxUkXz_X6SqTpujEAM0zXOCzwlR8qK3iREmHjUnhEvRCk6_HO3lx81pzl8xJp0S6klzTClbdQLTk-bnnUkTFBcmFEdU7gFV59YvxRQYUFl8TMiE4iYI6Ob6E70IsKASkTdlSYAGCENyxVlkYZ4zcmFYLOQqqWmBKf22cd4vAVCCvI4hQy1jClqnWMCWyk7GhVxQn8DUYE2wkKoceWfhafN4NHOGZ7t41nx-d313ddPefnz_4erytu0FxaVdUaWs5UzZARvCOqmAqM4KGA0WXIKEDjOwVhFlVkqN3dAzywWWnHNlazvOmrdb3_XSexgshJLMrNfJeZN-6GicPnwJ7l5P8btmnEvWsWrwZmvQu_gPg8MXG73eja2KX--qp_htgVy0d3nTURMgLlkTSgnhVAr6fxRzwignAlf05RadzAzahTHWwnaD60uquOikkLJS53-h6hmgDqCu2ejq_YHg1VZgU8w5wfjwSYL1Zhv3vvViv6kP3J_1Y78AVePfrQ |
| CitedBy_id | crossref_primary_10_1111_sji_12365 crossref_primary_10_1016_j_imlet_2014_07_004 crossref_primary_10_3390_cancers11030418 crossref_primary_10_1073_pnas_1510518113 crossref_primary_10_1080_21645515_2016_1193277 crossref_primary_10_4049_jimmunol_1402535 crossref_primary_10_1038_srep39250 crossref_primary_10_3390_cancers13102495 crossref_primary_10_1038_gt_2014_12 crossref_primary_10_1186_s12934_015_0290_9 crossref_primary_10_4049_jimmunol_1401243 crossref_primary_10_4161_onci_20982 crossref_primary_10_4049_jimmunol_1202592 crossref_primary_10_1016_j_jconrel_2022_07_036 crossref_primary_10_3892_ol_2017_7607 crossref_primary_10_1016_j_mce_2013_06_003 crossref_primary_10_1186_s12967_016_0905_x crossref_primary_10_1186_1756_8722_7_15 crossref_primary_10_15252_emmm_201606593 crossref_primary_10_1007_s10549_013_2410_8 crossref_primary_10_4049_jimmunol_1203216 crossref_primary_10_1155_2013_869718 crossref_primary_10_1007_s00262_016_1938_y crossref_primary_10_3390_vaccines4020008 crossref_primary_10_1038_cr_2016_157 crossref_primary_10_1186_s12885_019_5595_3 crossref_primary_10_3390_cancers12030590 crossref_primary_10_1371_journal_pone_0117778 crossref_primary_10_1016_j_imlet_2022_12_002 crossref_primary_10_1038_nrc_2016_91 crossref_primary_10_1111_sji_12387 crossref_primary_10_1158_1078_0432_CCR_16_0044 crossref_primary_10_1111_nyas_12125 crossref_primary_10_1002_advs_202304818 crossref_primary_10_1021_acs_molpharmaceut_3c00330 crossref_primary_10_1002_eji_202149515 crossref_primary_10_1371_journal_pone_0067453 crossref_primary_10_3389_fimmu_2015_00288 crossref_primary_10_1093_abbs_gms089 crossref_primary_10_3389_fimmu_2015_00243 crossref_primary_10_1371_journal_pone_0041897 crossref_primary_10_3389_fimmu_2015_00091 crossref_primary_10_1080_21691401_2016_1178131 crossref_primary_10_3390_antib11010008 crossref_primary_10_3390_vaccines8040565 crossref_primary_10_4049_jimmunol_1300975 crossref_primary_10_7774_cevr_2014_3_2_227 crossref_primary_10_1155_2015_785634 crossref_primary_10_3389_fimmu_2018_00744 crossref_primary_10_1177_15353702231191185 crossref_primary_10_2217_imt_13_169 crossref_primary_10_1007_s13139_021_00706_6 crossref_primary_10_3389_fimmu_2024_1292059 crossref_primary_10_1016_j_vaccine_2012_08_051 crossref_primary_10_1002_eji_201344076 crossref_primary_10_1016_j_biopha_2023_115758 crossref_primary_10_1016_j_smim_2023_101762 crossref_primary_10_3389_fimmu_2019_00009 crossref_primary_10_3390_pharmaceutics12070663 crossref_primary_10_1186_bcr3184 crossref_primary_10_3389_fimmu_2021_786286 crossref_primary_10_3389_fonc_2020_605633 crossref_primary_10_1016_j_intimp_2019_05_037 |
| Cites_doi | 10.1073/pnas.1019547108 10.4049/jimmunol.175.7.4265 10.1038/35052073 10.1158/0008-5472.CAN-05-0938 10.1038/375151a0 10.1158/1078-0432.CCR-08-3321 10.1111/j.1749-6632.2009.04933.x 10.1084/jem.194.6.769 10.1084/jem.20091918 10.1182/blood-2006-10-051318 10.1016/S0264-410X(00)00493-X 10.1084/jem.20090247 10.1126/science.3798106 10.1200/JCO.2010.30.7744 10.1158/0008-5472.CAN-10-1322 10.1016/S0264-410X(02)00741-7 10.1083/jcb.151.3.673 10.1158/0008-5472.CAN-08-2654 10.1016/S0198-8859(99)00003-8 10.1038/nrc2656 10.1089/hum.2009.202 10.1084/jem.20091921 10.4049/jimmunol.163.2.1037 10.1158/1078-0432.CCR-11-0891 10.1158/1078-0432.CCR-08-1257 10.1007/s00109-011-0794-7 10.1084/jem.181.6.2109 10.1126/science.1136080 10.1073/pnas.0711976105 10.1146/annurev.immunol.23.021704.115825 10.1038/nri2173 10.1158/0008-5472.CAN-05-4018 10.1186/1471-2407-9-386 10.1084/jem.20111171 10.1615/CritRevImmunol.v20.i1.20 10.1158/1078-0432.CCR-10-2563 10.4049/jimmunol.174.9.5481 10.1093/jnci/57.6.1211 10.1126/science.1129139 10.1023/A:1006438507898 10.1016/S0952-7915(98)80228-8 10.1038/nm1592 10.1677/erc.0.0090033 10.1084/jem.20052005 10.1084/jem.20032220 10.1007/s002620050268 10.1093/neuonc/noq071 10.1038/nri724 10.1016/j.biomaterials.2011.03.015 10.1016/j.immuni.2005.02.003 10.1006/cimm.1995.1109 10.1084/jem.20021598 10.1002/eji.200939748 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2012 BioMed Central Ltd. Copyright ©2011 Wang et al.; licensee BioMed Central Ltd. 2011 Wang et al.; licensee BioMed Central Ltd. |
| Copyright_xml | – notice: COPYRIGHT 2012 BioMed Central Ltd. – notice: Copyright ©2011 Wang et al.; licensee BioMed Central Ltd. 2011 Wang et al.; licensee BioMed Central Ltd. |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 7T5 H94 5PM |
| DOI | 10.1186/bcr3135 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic Immunology Abstracts AIDS and Cancer Research Abstracts PubMed Central (Full Participant titles) |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic AIDS and Cancer Research Abstracts Immunology Abstracts |
| DatabaseTitleList | MEDLINE - Academic MEDLINE AIDS and Cancer Research Abstracts |
| Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Anatomy & Physiology |
| EISSN | 1465-542X |
| EndPage | R39 |
| ExternalDocumentID | oai_biomedcentral_com_bcr3135 A284576566 10_1186_bcr3135 22397502 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GeographicLocations | United States |
| GeographicLocations_xml | – name: United States |
| GrantInformation_xml | – fundername: PHS HHS grantid: P01A1081677 – fundername: NIAID NIH HHS grantid: AI051573 – fundername: NIAID NIH HHS grantid: R01 AI013013 – fundername: Howard Hughes Medical Institute – fundername: NIAID NIH HHS grantid: AI13013 |
| GroupedDBID | --- 04C 0R~ 23N 2VQ 2WC 4.4 53G 5GY 5VS 6J9 AAFWJ AAJSJ AAWTL ACGFO ACGFS ACJQM ACMJI ACPRK ACRMQ ADBBV ADFRT ADINQ ADUKV AENEX AHBYD AHMBA AHSBF ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIAM AOIJS BAPOH BAWUL BCNDV BFQNJ BMC BMSDO C24 C6C CGR CS3 CUY CVF DIK DU5 E3Z EBD EBLON EBS ECM EIF EIHBH EJD F5P GROUPED_DOAJ GX1 H13 HYE HZ~ IAO ICW IHR INH INR ITC KQ8 NPM O5R O5S O9- OK1 P2P PGMZT PQQKQ RBZ ROL RPM RSV SBL SOJ TR2 U2A WOQ AAYXX CITATION 7X8 7T5 H94 3V. 7X7 8FI 8FJ ABUWG ABVAZ AFGXO AFKRA AFNRJ AFPKN AHYZX BENPR BPHCQ BVXVI C1A CCPQU FYUFA HMCUK LGEZI LOTEE NADUK NXXTH PIMPY PROAC UKHRP ZA5 5PM |
| ID | FETCH-LOGICAL-b520t-9288cc438cd0a13768e187c5efa0546e6e703ecc818a988f7db3c45064448c223 |
| IEDL.DBID | RPM |
| ISSN | 1465-542X 1465-5411 |
| IngestDate | Tue Sep 17 20:40:53 EDT 2024 Wed May 22 07:15:53 EDT 2024 Fri Oct 25 04:24:48 EDT 2024 Fri Oct 25 07:07:12 EDT 2024 Tue Nov 19 21:35:48 EST 2024 Tue Nov 12 23:44:39 EST 2024 Fri Nov 22 01:45:20 EST 2024 Tue Oct 15 23:48:26 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Language | English |
| License | This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-b520t-9288cc438cd0a13768e187c5efa0546e6e703ecc818a988f7db3c45064448c223 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3446373/ |
| PMID | 22397502 |
| PQID | 1041324150 |
| PQPubID | 23479 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3446373 biomedcentral_primary_oai_biomedcentral_com_bcr3135 proquest_miscellaneous_1221142652 proquest_miscellaneous_1041324150 gale_infotracmisc_A284576566 gale_infotracacademiconefile_A284576566 crossref_primary_10_1186_bcr3135 pubmed_primary_22397502 |
| PublicationCentury | 2000 |
| PublicationDate | 2012-03-07 |
| PublicationDateYYYYMMDD | 2012-03-07 |
| PublicationDate_xml | – month: 03 year: 2012 text: 2012-03-07 day: 07 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Breast cancer research : BCR |
| PublicationTitleAlternate | Breast Cancer Res |
| PublicationYear | 2012 |
| Publisher | BioMed Central Ltd BioMed Central |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central |
| References | 12615426 - Vaccine. 2003 Mar 28;21(13-14):1317-26 19564349 - J Exp Med. 2009 Jul 6;206(7):1589-602 7903196 - Cancer Res. 1993 Dec 15;53(24):5864-6 11910899 - Nat Rev Immunol. 2002 Feb;2(2):85-95 19584156 - Clin Cancer Res. 2009 Jul 15;15(14):4612-21 18980988 - Clin Cancer Res. 2008 Nov 1;14(21):6933-43 7539040 - J Exp Med. 1995 Jun 1;181(6):2109-17 21632857 - Clin Cancer Res. 2011 Jul 15;17(14):4844-53 11252954 - Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37 10408800 - Hum Immunol. 1999 Jun;60(6):510-5 21845448 - J Mol Med (Berl). 2011 Dec;89(12):1231-40 21135147 - Clin Cancer Res. 2011 Mar 15;17(6):1603-15 19878568 - BMC Cancer. 2009;9:386 16177066 - J Immunol. 2005 Oct 1;175(7):4265-73 11914181 - Endocr Relat Cancer. 2002 Mar;9(1):33-44 10395702 - J Immunol. 1999 Jul 15;163(2):1037-44 16551258 - Annu Rev Immunol. 2006;24:519-40 19769731 - Ann N Y Acad Sci. 2009 Sep;1174:6-17 16505141 - J Exp Med. 2006 Mar 20;203(3):607-17 19536107 - Nat Rev Cancer. 2009 Jul;9(7):463-75 20940398 - Cancer Res. 2010 Nov 1;70(21):8368-77 21474175 - Biomaterials. 2011 Jul;32(20):4574-83 10770269 - Crit Rev Immunol. 2000;20(1):17-56 15024047 - J Exp Med. 2004 Mar 15;199(6):815-24 3798106 - Science. 1987 Jan 9;235(4785):177-82 10910070 - Cancer Res. 2000 Jul 1;60(13):3569-76 9794842 - Curr Opin Immunol. 1998 Oct;10(5):588-94 22065672 - J Exp Med. 2011 Nov 21;208(12):2357-66 20604681 - Hum Gene Ther. 2010 Dec;21(12):1697-706 19830741 - Eur J Immunol. 2010 Jan;40(1):36-46 7505195 - Cancer Res. 1994 Jan 1;54(1):16-20 17204652 - Science. 2007 Jan 5;315(5808):107-11 12486105 - J Exp Med. 2002 Dec 16;196(12):1627-38 1069859 - J Natl Cancer Inst. 1976 Dec;57(6):1211-6 9699670 - Cancer Res. 1998 Aug 1;58(15):3385-90 17008531 - Science. 2006 Sep 29;313(5795):1960-4 17558415 - Nat Med. 2007 Jul;13(7):843-50 21149657 - J Clin Oncol. 2011 Jan 20;29(3):330-6 15843546 - J Immunol. 2005 May 1;174(9):5481-9 20615924 - Neuro Oncol. 2010 Oct;12(10):1071-7 16707474 - Cancer Res. 2006 May 15;66(10):5452-60 12006513 - Clin Cancer Res. 2002 May;8(5):1014-8 15780993 - Immunity. 2005 Mar;22(3):371-83 7912166 - Cancer Res. 1994 Jul 1;54(13):3387-90 11062267 - J Cell Biol. 2000 Oct 30;151(3):673-84 10470176 - Anticancer Res. 1999 Jul-Aug;19(4A):2471-5 11072789 - Breast Cancer Res Treat. 2000 Aug;62(3):245-52 20156971 - J Exp Med. 2010 Mar 15;207(3):637-50 7758125 - Cell Immunol. 1995 Jun;163(1):148-56 20156973 - J Exp Med. 2010 Mar 15;207(3):651-67 17853902 - Nat Rev Immunol. 2007 Oct;7(10):790-802 19258510 - Cancer Res. 2009 Mar 15;69(6):2685-93 16061687 - Cancer Res. 2005 Aug 1;65(15):7007-12 17327412 - Blood. 2007 Jun 15;109(12):5346-54 8640846 - Cancer Immunol Immunother. 1996 Mar;42(3):179-84 11257398 - Vaccine. 2001 Mar 21;19(17-19):2598-606 11560993 - J Exp Med. 2001 Sep 17;194(6):769-79 18256187 - Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2574-9 7753172 - Nature. 1995 May 11;375(6527):151-5 21262813 - Proc Natl Acad Sci U S A. 2011 Feb 8;108(6):2384-9 7819273 - Biochim Biophys Acta. 1994 Dec 30;1198(2-3):165-84 J Baselga (2934_CR2) 2009; 9 A Granelli-Piperno (2934_CR28) 2005; 175 Y Yarden (2934_CR1) 2001; 2 H Bernhard (2934_CR9) 2002; 9 MP Longhi (2934_CR34) 2009; 206 RT Reilly (2934_CR61) 2000; 60 LC Bonifaz (2934_CR31) 2004; 199 D Dudziak (2934_CR25) 2007; 315 A Dimitriadis (2934_CR16) 2009; 9 F Rohrbach (2934_CR17) 2005; 174 K Inaba (2934_CR24) 1995; 163 D Slamon (2934_CR3) 1987; 235 M Disis (2934_CR6) 1994; 54 K Mahnke (2934_CR29) 2000; 151 ML Disis (2934_CR8) 2000; 62 D Hawiger (2934_CR30) 2001; 194 SM Pupa (2934_CR5) 1993; 53 R Bos (2934_CR51) 2010; 70 JS Dela Cruz (2934_CR15) 2003; 21 B Wang (2934_CR32) 2009; 1174 XG Gu (2934_CR45) 1998; 58 L Bozzacco (2934_CR60) 2010; 40 H Okada (2934_CR39) 2011; 29 S Quezada (2934_CR57) 2010; 207 M Caskey (2934_CR35) 2011; 208 AD Gritzapis (2934_CR44) 2006; 66 CL Vanderlugt (2934_CR55) 2002; 2 PJ Tacken (2934_CR26) 2007; 7 RL Ward (2934_CR7) 1999; 60 KL Knutson (2934_CR52) 2002; 8 JS Thomann (2934_CR21) 2011; 32 K Mahnke (2934_CR59) 2005; 65 TM Foy (2934_CR14) 2001; 19 J Idoyaga (2934_CR27) 2011; 108 B Fisk (2934_CR11) 1995; 181 RM Prins (2934_CR40) 2011; 17 MA Morse (2934_CR38) 2011; 17 Y Rongcun (2934_CR43) 1999; 163 A Perez-Diez (2934_CR56) 2007; 109 L Bonifaz (2934_CR33) 2002; 196 J Galon (2934_CR46) 2006; 313 Y Xie (2934_CR58) 2010; 207 I Yoshino (2934_CR10) 1994; 54 MR Rosenfeld (2934_CR41) 2010; 12 M Camus (2934_CR47) 2009; 69 PA Cohen (2934_CR53) 2000; 20 P Taylor (2934_CR13) 1996; 42 C Trumpfheller (2934_CR48) 2008; 105 CJ Cornell Jr (2934_CR37) 1976; 57 F Castellino (2934_CR50) 2006; 24 PA Darrah (2934_CR36) 2007; 13 A Sloots (2934_CR18) 2008; 14 W Jiang (2934_CR23) 1995; 375 A Corthay (2934_CR54) 2005; 22 M Peiper (2934_CR12) 1999; 19 YS Kim (2934_CR20) 2010; 21 C Trumpfheller (2934_CR42) 2006; 203 NE Hynes (2934_CR4) 1994; 1198 H Wei (2934_CR19) 2009; 15 DM Pardoll (2934_CR49) 1998; 10 IG Zizzari (2934_CR22) 2011; 89 |
| References_xml | – volume: 108 start-page: 2384 year: 2011 ident: 2934_CR27 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.1019547108 contributor: fullname: J Idoyaga – volume: 175 start-page: 4265 year: 2005 ident: 2934_CR28 publication-title: J Immunol doi: 10.4049/jimmunol.175.7.4265 contributor: fullname: A Granelli-Piperno – volume: 2 start-page: 127 year: 2001 ident: 2934_CR1 publication-title: Nat Rev Mol Cell Biol doi: 10.1038/35052073 contributor: fullname: Y Yarden – volume: 65 start-page: 7007 year: 2005 ident: 2934_CR59 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-05-0938 contributor: fullname: K Mahnke – volume: 375 start-page: 151 year: 1995 ident: 2934_CR23 publication-title: Nature doi: 10.1038/375151a0 contributor: fullname: W Jiang – volume: 15 start-page: 4612 year: 2009 ident: 2934_CR19 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-08-3321 contributor: fullname: H Wei – volume: 1174 start-page: 6 year: 2009 ident: 2934_CR32 publication-title: Ann N Y Acad Sci doi: 10.1111/j.1749-6632.2009.04933.x contributor: fullname: B Wang – volume: 194 start-page: 769 year: 2001 ident: 2934_CR30 publication-title: J Exp Med doi: 10.1084/jem.194.6.769 contributor: fullname: D Hawiger – volume: 207 start-page: 637 year: 2010 ident: 2934_CR57 publication-title: J Exp Med doi: 10.1084/jem.20091918 contributor: fullname: S Quezada – volume: 109 start-page: 5346 year: 2007 ident: 2934_CR56 publication-title: Blood doi: 10.1182/blood-2006-10-051318 contributor: fullname: A Perez-Diez – volume: 19 start-page: 2598 year: 2001 ident: 2934_CR14 publication-title: Vaccine doi: 10.1016/S0264-410X(00)00493-X contributor: fullname: TM Foy – volume: 206 start-page: 1589 year: 2009 ident: 2934_CR34 publication-title: J Exp Med doi: 10.1084/jem.20090247 contributor: fullname: MP Longhi – volume: 235 start-page: 177 year: 1987 ident: 2934_CR3 publication-title: Science doi: 10.1126/science.3798106 contributor: fullname: D Slamon – volume: 29 start-page: 330 year: 2011 ident: 2934_CR39 publication-title: J Clin Oncol doi: 10.1200/JCO.2010.30.7744 contributor: fullname: H Okada – volume: 70 start-page: 8368 year: 2010 ident: 2934_CR51 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-10-1322 contributor: fullname: R Bos – volume: 53 start-page: 5864 year: 1993 ident: 2934_CR5 publication-title: Cancer Res contributor: fullname: SM Pupa – volume: 21 start-page: 1317 year: 2003 ident: 2934_CR15 publication-title: Vaccine doi: 10.1016/S0264-410X(02)00741-7 contributor: fullname: JS Dela Cruz – volume: 151 start-page: 673 year: 2000 ident: 2934_CR29 publication-title: J Cell Biol doi: 10.1083/jcb.151.3.673 contributor: fullname: K Mahnke – volume: 69 start-page: 2685 year: 2009 ident: 2934_CR47 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-08-2654 contributor: fullname: M Camus – volume: 60 start-page: 510 year: 1999 ident: 2934_CR7 publication-title: Hum Immunol doi: 10.1016/S0198-8859(99)00003-8 contributor: fullname: RL Ward – volume: 9 start-page: 463 year: 2009 ident: 2934_CR2 publication-title: Nat Rev Cancer doi: 10.1038/nrc2656 contributor: fullname: J Baselga – volume: 54 start-page: 16 year: 1994 ident: 2934_CR6 publication-title: Cancer Res contributor: fullname: M Disis – volume: 54 start-page: 3387 year: 1994 ident: 2934_CR10 publication-title: Cancer Res contributor: fullname: I Yoshino – volume: 21 start-page: 1697 year: 2010 ident: 2934_CR20 publication-title: Hum Gene Ther doi: 10.1089/hum.2009.202 contributor: fullname: YS Kim – volume: 207 start-page: 651 year: 2010 ident: 2934_CR58 publication-title: J Exp Med doi: 10.1084/jem.20091921 contributor: fullname: Y Xie – volume: 163 start-page: 1037 year: 1999 ident: 2934_CR43 publication-title: J Immunol doi: 10.4049/jimmunol.163.2.1037 contributor: fullname: Y Rongcun – volume: 17 start-page: 4844 year: 2011 ident: 2934_CR38 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-11-0891 contributor: fullname: MA Morse – volume: 14 start-page: 6933 year: 2008 ident: 2934_CR18 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-08-1257 contributor: fullname: A Sloots – volume: 8 start-page: 1014 year: 2002 ident: 2934_CR52 publication-title: Clin Cancer Res contributor: fullname: KL Knutson – volume: 89 start-page: 1231 year: 2011 ident: 2934_CR22 publication-title: J Mol Med (Berl) doi: 10.1007/s00109-011-0794-7 contributor: fullname: IG Zizzari – volume: 181 start-page: 2109 year: 1995 ident: 2934_CR11 publication-title: J Exp Med doi: 10.1084/jem.181.6.2109 contributor: fullname: B Fisk – volume: 19 start-page: 2471 year: 1999 ident: 2934_CR12 publication-title: Anticancer Res contributor: fullname: M Peiper – volume: 315 start-page: 107 year: 2007 ident: 2934_CR25 publication-title: Science doi: 10.1126/science.1136080 contributor: fullname: D Dudziak – volume: 105 start-page: 2574 year: 2008 ident: 2934_CR48 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0711976105 contributor: fullname: C Trumpfheller – volume: 24 start-page: 519 year: 2006 ident: 2934_CR50 publication-title: Annu Rev Immunol doi: 10.1146/annurev.immunol.23.021704.115825 contributor: fullname: F Castellino – volume: 7 start-page: 790 year: 2007 ident: 2934_CR26 publication-title: Nat Rev Immunol doi: 10.1038/nri2173 contributor: fullname: PJ Tacken – volume: 58 start-page: 3385 year: 1998 ident: 2934_CR45 publication-title: Cancer Res contributor: fullname: XG Gu – volume: 66 start-page: 5452 year: 2006 ident: 2934_CR44 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-05-4018 contributor: fullname: AD Gritzapis – volume: 9 start-page: 386 year: 2009 ident: 2934_CR16 publication-title: BMC Cancer doi: 10.1186/1471-2407-9-386 contributor: fullname: A Dimitriadis – volume: 208 start-page: 2357 year: 2011 ident: 2934_CR35 publication-title: J Exp Med doi: 10.1084/jem.20111171 contributor: fullname: M Caskey – volume: 20 start-page: 17 year: 2000 ident: 2934_CR53 publication-title: Crit Rev Immunol doi: 10.1615/CritRevImmunol.v20.i1.20 contributor: fullname: PA Cohen – volume: 17 start-page: 1603 year: 2011 ident: 2934_CR40 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-10-2563 contributor: fullname: RM Prins – volume: 1198 start-page: 165 year: 1994 ident: 2934_CR4 publication-title: Biochim Biophys Acta contributor: fullname: NE Hynes – volume: 174 start-page: 5481 year: 2005 ident: 2934_CR17 publication-title: J Immunol doi: 10.4049/jimmunol.174.9.5481 contributor: fullname: F Rohrbach – volume: 57 start-page: 1211 year: 1976 ident: 2934_CR37 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/57.6.1211 contributor: fullname: CJ Cornell Jr – volume: 313 start-page: 1960 year: 2006 ident: 2934_CR46 publication-title: Science doi: 10.1126/science.1129139 contributor: fullname: J Galon – volume: 62 start-page: 245 year: 2000 ident: 2934_CR8 publication-title: Breast Cancer Res Treat doi: 10.1023/A:1006438507898 contributor: fullname: ML Disis – volume: 10 start-page: 588 year: 1998 ident: 2934_CR49 publication-title: Curr Opin Immunol doi: 10.1016/S0952-7915(98)80228-8 contributor: fullname: DM Pardoll – volume: 13 start-page: 843 year: 2007 ident: 2934_CR36 publication-title: Nat Med doi: 10.1038/nm1592 contributor: fullname: PA Darrah – volume: 9 start-page: 33 year: 2002 ident: 2934_CR9 publication-title: Endocr Relat Cancer doi: 10.1677/erc.0.0090033 contributor: fullname: H Bernhard – volume: 203 start-page: 607 year: 2006 ident: 2934_CR42 publication-title: J Exp Med doi: 10.1084/jem.20052005 contributor: fullname: C Trumpfheller – volume: 199 start-page: 815 year: 2004 ident: 2934_CR31 publication-title: J Exp Med doi: 10.1084/jem.20032220 contributor: fullname: LC Bonifaz – volume: 42 start-page: 179 year: 1996 ident: 2934_CR13 publication-title: Cancer Immunol Immunother doi: 10.1007/s002620050268 contributor: fullname: P Taylor – volume: 12 start-page: 1071 year: 2010 ident: 2934_CR41 publication-title: Neuro Oncol doi: 10.1093/neuonc/noq071 contributor: fullname: MR Rosenfeld – volume: 2 start-page: 85 year: 2002 ident: 2934_CR55 publication-title: Nat Rev Immunol doi: 10.1038/nri724 contributor: fullname: CL Vanderlugt – volume: 60 start-page: 3569 year: 2000 ident: 2934_CR61 publication-title: Cancer Res contributor: fullname: RT Reilly – volume: 32 start-page: 4574 year: 2011 ident: 2934_CR21 publication-title: Biomaterials doi: 10.1016/j.biomaterials.2011.03.015 contributor: fullname: JS Thomann – volume: 22 start-page: 371 year: 2005 ident: 2934_CR54 publication-title: Immunity doi: 10.1016/j.immuni.2005.02.003 contributor: fullname: A Corthay – volume: 163 start-page: 148 year: 1995 ident: 2934_CR24 publication-title: Cell Immunol doi: 10.1006/cimm.1995.1109 contributor: fullname: K Inaba – volume: 196 start-page: 1627 year: 2002 ident: 2934_CR33 publication-title: J Exp Med doi: 10.1084/jem.20021598 contributor: fullname: L Bonifaz – volume: 40 start-page: 36 year: 2010 ident: 2934_CR60 publication-title: Eur J Immunol doi: 10.1002/eji.200939748 contributor: fullname: L Bozzacco |
| SSID | ssj0017858 |
| Score | 2.36552 |
| Snippet | Given their relative simplicity of manufacture and ability to be injected repeatedly, vaccines in a protein format are attractive for breast and other cancers.... Introduction Given their relative simplicity of manufacture and ability to be injected repeatedly, vaccines in a protein format are attractive for breast and... INTRODUCTIONGiven their relative simplicity of manufacture and ability to be injected repeatedly, vaccines in a protein format are attractive for breast and... INTRODUCTION: Given their relative simplicity of manufacture and ability to be injected repeatedly, vaccines in a protein format are attractive for breast and... |
| SourceID | pubmedcentral biomedcentral proquest gale crossref pubmed |
| SourceType | Open Access Repository Aggregation Database Index Database |
| StartPage | R39 |
| SubjectTerms | Animal models Animals Antibodies, Monoclonal - genetics Antibodies, Monoclonal - immunology Antigen (tumor-associated) Antigen presentation Antigen processing Breast cancer Breast Neoplasms - immunology Breast Neoplasms - pathology Cancer vaccines Cancer Vaccines - genetics Cancer Vaccines - immunology CD4 antigen CD4-Positive T-Lymphocytes - immunology CD4-Positive T-Lymphocytes - metabolism CD40 antigen CD8 antigen CD8-Positive T-Lymphocytes - immunology CD8-Positive T-Lymphocytes - metabolism Cell Line, Tumor Cross-reactivity Dendritic cells Dendritic Cells - immunology Epidermal growth factor receptors ErbB-2 protein Female Gene mutations Genetic aspects Genetic engineering Humans Immune response Immunity, Humoral Immunogenicity Interferon Interferon-gamma - metabolism Lymphocytes B Lymphocytes T Mammary gland Mammary Neoplasms, Experimental - immunology Mammary Neoplasms, Experimental - pathology Mice Mice, Inbred Strains Mice, Transgenic Monoclonal antibodies Physiological aspects Poly I-C - immunology Poly I-C - pharmacology Protein Structure, Tertiary - genetics Receptor, ErbB-2 - genetics Receptor, ErbB-2 - immunology Recombinant Proteins - genetics Recombinant Proteins - immunology T-Lymphocytes - immunology Tumors Vaccines |
| SummonAdditionalLinks | – databaseName: BiomedCentral dbid: RBZ link: http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZokRAXHi2PhYKmEoJT1CROYue4wFZ7gUMpEuISxY_ASiRB2eTAr-Gv8tlJl02FEOI8Htmx5_FNPDNm7IV7h1KleRgoHUoEKFZBpUQVpEYKE5pSKF_luv4g3n-Sb1euTc7pn2_wI5mdKd3xiKcH7CYihcQJ8cXrz7uLAiH9E5zQ9zRIkyga62L3Ga9Vsn-bOaDrZnjPD81zJPeczvndf1juPXZnQpS0HEXgPrthmyN2vGwQTdc_6CX5HE__8_yI3Xo3XaUfs5-XPgccnovaigADqWmboB4c-DTUD3XbEXbdNeuk9eoiPmvsQH1Lte8ESjBXxr-SQO7X_5YQ2kNItmChXQcKQxtXfWKpGxNxLaYpe5paQ2Dsl3IDdErKJcb3pJ0AdmCnGtbrAft4vrp8sw6m1xoClcZhH-SxlFonXGoTlhHslrSRFDq1VQlYmNnMwrhAYIAQylzKShjFdeL65SFC1EApD9khPtQ-ZsQrmydpbGweyqTkQsXKhqHOhQ15nmm5YHx2pMX3sTNH4XplzylQ22I6kgWjq4PfMfgQSGa_h7xyAlE45Qa7LqcaBSzLtckqlnDmCNAAgRfsZDYSSqln5NMrkSocyWWyNbYdtpgRsMHBpvAvY-LYlThnabxgj0Yx3K0YG5UD5YEiZgI624M5pdl89X3DOUJ_LviT_9q9p-w2sGLs0-_ECTvsu8E-YwdbMzz3GvkLCmc4Hg priority: 500 providerName: BioMedCentral |
| Title | Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/22397502 https://search.proquest.com/docview/1041324150 https://search.proquest.com/docview/1221142652 http://dx.doi.org/10.1186/bcr3135 https://pubmed.ncbi.nlm.nih.gov/PMC3446373 |
| Volume | 14 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF6RHhAXBC2PQIkGCcHJ9WNj7_oYSqogVIRKkRAXy7tel0i1XSX2gV_DX-XbjR3qHjhwyWV35I3n9c16Hoy9sXMoVZwGntKBRIBiFFRKlF5cSFEERS6Uq3JdfRWfv8sPS9smJx5qYVzSvlbrk_q6OqnXP11u5U2l_SFPzP9yfsoRw3DB_QmbABsOIXr_6UBIN5QTFiD24nkY7iplgaMTX-kND7kdVgOnmMJXRnfK3K9H3umujb7lpMYJlLc80tkj9rCHkrTYHfkxu2fqQ3a0qBFGV7_oLbnkTndrfsjun_ff0I_Y70uX_A2XRU1JwH9UN7VXdRZ1FtR2VbMhvG7bpZNWy4vIr01HbUOVawFKsFOFG49A9s5_S4jpIR1bkNC-9URBa1t2Ymizy8A1eEzeUt8TAnuv8jVgKSmbEd-StpK3ATlVMFtP2Lez5eXpyuvHNHgqjoLWSyMptZ5zqYsgD2GwpAml0LEpc-DBxCQGVgWSAmiQp1KWolBcz22jPISGGpx4yg7wR81zRrw06TyOCpMGcp5zoSJlgkCnwgQ8TbScMj5iV3aza8mR2SbZ4xXoa9bze8poYOqewMU-Mvm75Z1ldma1GuQ674sTcCzbHytbwIsjMgP2nbLj0U5oox4tvx7EJbNLNoWtNk23xROBFyxeCv6xJ4psbXMSR1P2bCdi-xMPIjtlYiR8o3cwXoH-uIbhvb68-G_Kl-wBgGLkcu_EMTtoN515xSbbopshDPn4aeauMvB78f7HzKnjH508O8o |
| link.rule.ids | 108,230,315,729,782,786,866,887,24946,27933,27934,53800,53802,75821,75822 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZokYALj5ZCoMAgITil8dpJ7BxXZatFdCsEi8Qtih8LKzXZKpsc-DX8VcZOsjQ9cOjZHiVZfzPzzXoehLxzcyhVktFQaSoxQLEKVUqswsRIYagphPJVrvNv4uKH_DhzbXKSoRbGJ-1rtT6pLsuTav3L51ZelToa8sSiL4tTjjEMFzzaI3dRXykdgvT-8kBIP5YTbUASJvFk0tXKIpNOI6VrPuFuXA26xQy9JbtR6H458k83rfQ1NzVOobzmk84e3fJrHpOHPQmFabf8hNyx1QE5nFYYgJe_4T34tFD_f_sBubfob98PyZ-lTxtHZwebFSBzhGpThWXr-KqBpi03NeBBuf6eMJ99ZVFlW2g2UPrmoYAWzvjBCuBuC7awrgziaosisGtaYWDtClYs1F3ursXHFA303SRw789ijYQWlMulb0A7zNYoDiUavKfk-9lseToP-wEPoUoYbcKMSal1zKU2tJigqZN2IoVO7KpAJpna1KI9QowhqSgyKVfCKK5j12IPg0qNJ3hE9vFD7XMCfGWzOGHGZlTGBReKKUupzoSlPEu1DAgfHXN-1TXzyF177fEKanre4yQgMIBhJ-CjJpn-2_LBgSR39gDFddGXNeBruc5a-RT9P8Z0yJoDcjzaiXqsR8tvB5jlbsklv1V2027xicg0HNOi_9nDmKuKThMWkGcdNHdvPEA9IGIE2tFvMF5BrPpW4z02X9xa8g25P18uzvPzTxefX5IHSDeZz-ATx2S_qVv7iuxtTfvaK_BfDsNOUw |
| linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELZokSouPFoeCwUGCcEpjWMnsXNctbtaBK0qKBK3KH4EIjXZVTY58Gv4q4y92aXpgQOcPVaS9Tcz36znQchbN4dSJRkNlKYSAxSrUKVEGSRGCkNNIZSvcl18ERff5NnMtcnZjfrySftaVSfNdX3SVD98buWq1uE2Tyy8PD_lGMNwwcOVKcM9chd1lrJtoD5cIAjpR3OiHUiCJI6iTb0ssuk0VLrlEXcja9A1Zugx2a1i9-uRj7ptqW-4qnEa5Q2_NH_wH1_0kNwfyChMNyKPyB3bHJKjaYOBeP0T3oFPD_X_ux-Sg_PhFv6I_Lry6ePo9GBZAjJIaJZNUPeOtxro-nrZAh6Y6_MJi9lnFja2h24JtW8iCmjpjB-wAO7WYA1VYxBfa9wCu-YVBipXuGKh3eTwWnxM0cHQVQJlvxcVEltQLqe-A-2w2-J2qNHwPSZf57Or00UwDHoIVMJoF2RMSq1jLrWhRYQmT9pICp3YskBGmdrUol1CrCG5KDIpS2EU17FrtYfBpcZTfEL28UPtMwK8tFmcMGMzKuOCC8WUpVRnwlKepVpOCB8ddb7aNPXIXZvt8QpqfD5gZUJgC4jdBh89yfSPyHsHlNzZBdyui6G8AV_LddjKp8gDMLZD9jwhxyNJ1Gc9Wn6zhVrullwSXGOX_RqfiIzDMS76FxnGXHV0mrAJebqB5-6Nt3CfEDEC7ug3GK8gXn3L8QGfz_9552tycHk2zz99uPj4gtxD1sl8Ip84Jvtd29uXZG9t-ldeh38DTbdQ0w |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Targeting+of+the+non-mutated+tumor+antigen+HER2%2Fneu+to+mature+dendritic+cells+induces+an+integrated+immune+response+that+protects+against+breast+cancer+in+mice&rft.jtitle=Breast+cancer+research+%3A+BCR&rft.au=Wang%2C+Bei&rft.au=Zaidi%2C+Neeha&rft.au=He%2C+Li-Zhen&rft.au=Zhang%2C+Li&rft.date=2012-03-07&rft.eissn=1465-542X&rft.volume=14&rft.issue=2&rft.spage=R39&rft.epage=R39&rft_id=info:doi/10.1186%2Fbcr3135&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1465-542X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1465-542X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1465-542X&client=summon |